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Introduction: Critically ill patients often require renal replacement therapy accompanied by thrombocytopenia.
Thrombocytopenia during heparin anticoagulation may be due to heparin-induced thrombocytopenia with need
for alternative anticoagulation. Therefore, we compared argatroban and lepirudin in critically ill surgical patients.
Methods: Following institutional review board approval and written informed consent, critically ill surgical patients
more than or equal to 18 years with suspected heparin-induced thrombocytopenia, were randomly assigned to
receive double-blind argatroban or lepirudin anticoagulation targeting an activated Partial Thromboplastin Time
(aPTT) of 1.5 to 2 times baseline. In patients requiring continuous renal replacement therapy we compared the
life-time of hemodialysis filters. We evaluated in all patients the incidence of bleeding and thrombembolic events.
Results: We identified 66 patients with suspected heparin-induced thrombocytopenia, including 28 requiring renal
replacement therapy. Mean filter lifetimes did not differ between groups (argatroban 32 ± 25 hours (n = 12) versus
lepirudin 27 ± 21 hours (n = 16), mean difference 5 hours, 95% CI −13 to 23, P = 0.227). Among all 66 patients,
relevant bleeding occurred in four argatroban- versus eleven lepirudin-patients (OR 3.9, 95% CI 1.1 to 14.0, P = 0.040). In
the argatroban-group, three thromboembolic events occurred compared to two in the lepirudin group (OR 0.7, 95% CI
0.1 to 4.4, P = 0.639). The incidence of confirmed heparin-induced thrombocytopenia was 23% (n = 15) in our study
population.
Conclusions: This first randomized controlled double-blind trial comparing two direct thrombin inhibitors showed
comparable effectiveness for renal replacement therapy, but suggests fewer bleeds in surgical patients with argatroban
anticoagulation.
Trial registration: Clinical Trials.gov NCT00798525. Registered 25 November 2008Introduction
Heparin is the standard anticoagulant in critically ill
patients [1]. However, anticoagulation remains a challenge
because these patients have an increased risk for thrombo-
embolism and for bleeding [2], often suffer from multior-
gan impairment and are often thrombocytopenic. Despite
multiple causes for thrombocytopenia, heparin-induced
thrombocytopenia (HIT) warrants special attention. HIT
is a pro-thrombotic syndrome caused by antibodies against
complexes of platelet factor 4 and heparin, which activate* Correspondence: tanja.treschan@med.uni-duesseldorf.de
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unless otherwise stated.platelets, causing platelet aggregation and hypercoagula-
bility [3]. Thus, in HIT the risk of thrombosis increases
paradoxically during heparin administration. The overall
incidence of confirmed HIT in critically ill patients in
general is relatively low, in the range of 0.5% [4], but
increases up to 28% in subgroups preselected by clinical
symptoms [5]. As soon as HIT is suspected, patients re-
quire an alternative anticoagulant [6]. At the time of this
study, two approved direct thrombin inhibitors, argatroban
and lepirudin, were available for alternative anticoagulation
in HIT patients, but no prospective comparative studies
between these drugs had been performed to date. In con-
trast to lepirudin, argatroban might be beneficial due to
its hepatic elimination, short half-life and thrombolytical Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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[7-9]. In critically ill patients disposed to developing HIT
and the need for renal replacement therapy, filter clotting
is a major complication, which also needs to be prevented
by appropriate alternative anticoagulation [10].
In this prospective randomized study we compared
argatroban and lepirudin to evaluate their efficacy and
safety in critically ill surgical patients with a special focus
on filter life time during continuous renal replacement
therapy.
Materials and methods
The Ethics Committee of the Medical Faculty,
Heinrich-Heine-University Düsseldorf, Germany and the
Bundesinstitut für Arzneimitel, EudraCT number 2006-
003122-28 approved this study (ClinicalTrials.gov number
NCT00798525. Registered 25 November 2008), which has
been performed in accordance with the Declaration of
Helsinki in its effective form. Written informed consent
was obtained from patients or their legal guardian. In
this double blind trial we included surgical intensive
care unit patients with expected ICU treatment >24 hours,
age ≥18 years and suspected HIT (decrease in platelet
count >50% from baseline, persisting for more than
24 hours, 4 T-Score >3 [11,12] or positive PF4/heparin
enzyme-linked immunosorbent assay). Exclusion criteria
were: active bleeding, intracranial surgery, spontaneous
activated partial thromoplastin time (aPTT) >60 seconds,
known HIT (treated with open label argatroban), adverse
events against study drugs and pregnancy.
Primary endpoint
The primary endpoint was a mean life-time of a maximum
of two consecutive filters in patients with continuous renal
replacement therapy.
Secondary endpoints (all patients) were: 1) relevant
bleeding [13]: moderate (transfusion required) or severe
(intracranial or hemodynamic compromise requiring
intervention); 2) transfusion requirements; 3) objectively
confirmed new thromboembolism; 4) anaphylactoid reac-
tions; 5) duration of intensive care unit and hospital
stay; 6) in-hospital mortality; and 7) hours until first
aPTT 55 to 65 seconds.
Study protocol
In case of suspected HIT, heparin was stopped and pa-
tients were randomized to argatroban (Mitsubishi Pharma
Europe, London, UK) or lepirudin (Celgene, Munich,
Germany), adjusted to an aPTT of 55 to 65 seconds
(1.5 to 2 times baseline (<37 seconds); Pathromtin
SL, Siemens Healthcare Diagnostic Products GmbH,
Marburg, Germany). Computer generated multi-block 1:1
randomizations were kept in sealed opaque envelopes.
Results from external heparin-induced platelet activationassay (HIPA) are usually available within approximately
seven days. Therefore, per protocol data collection was
limited to a maximum of seven days. In the case of a nega-
tive result of HIPA testing, heparin anticoagulation was
started again. In case of a positive HIPA test, alternative
anticoagulation was continued as long as considered ne-
cessary to treat or prevent thrombembolic complications.Preparation and dosing of study drugs
Study drugs were prepared by personnel not involved in
data collection and delivered to the intensive care unit
in neutral 50 ml syringes. The personnel preparing the
study drug were informed on the renal and hepatic func-
tion of each patient and filled the syringes accordingly
with different drug concentrations ensuring that the
treating physician always started with identical infusion
rates of 0.05 ml/kg/hour at initiation of treatment.
Lepirudin: 1) patients with continuous renal replace-
ment therapy: final concentration 0.1 mg/ml, initiated
as a continuous infusion of 5 μg/kg/hour; 2) patients
with moderate renal impairment (creatinine ≥1.3 mg/dl):
final concentration 0.2 mg/ml, initial infusion of 10 μg/
kg/hour; 3) patients without renal impairment (crea-
tinine <1.3 mg/dl): final concentration 1 mg/ml, initial in-
fusion 50 μg/kg/hour.
Argatroban: 1) patients without liver dysfunction: final
concentration 0.6 mg/ml, initiated as continuous infusion
of 0.5 μg/kg/minute; 2) patients with severe liver dysfunc-
tion (bilirubin of >4 mg/dl): final concentration 0.3 mg/ml,
initial infusion 0.25 μg/kg/minute. Study drug infusion
rates <0.1 ml/hour were assessed as a stop of infusion.Renal replacement therapy
Renal replacement therapy was initiated in the case of: 1)
fluid overload resistant to diuretic therapy (maximum dose
of furosemide 1,000 mg/day); 2) severe metabolic (renal)
acidosis, pH <7.2; 3) hyperkalemia >6.5 mmol; 4) uremic
symptoms (pericarditis, encephalopathy); 5) elevated serum
urea (>150 mg/day) or creatinine (>3.0 mg/dl); or 6) glom-
erular filtration rate <15 ml/minute. We performed con-
tinuous veno-venous hemodiafiltration via Niagara venous
catheters (13.5 french, 2 lumen, 20 cm, C.R. Bard GmbH,
Karlsruhe, Germany) using a saline primed dialysis circuit
with post dilution. Blood flow was adjusted to 120 to
150 ml/hour. Ultrafiltration rate depended on the individ-
ual goal of the daily net fluid balance per patient (0 to
300 ml/hour) using Ultraflux AV1000 filter (Fresenius
Medical Care, Bad Homburg, Germany). We used a
dialysate to ultrafiltration flow ratio of 1:1, resulting in a
filtration fraction of about 27%. Anticoagulation was ad-
justed to target aPTT prior to the start of dialysis. In case
of circuit clotting, a second system was initiated. In case
of repeated clotting, the study endpoint was reached and
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of these filters were not analyzed.
Measurements
For aPTT control, blood samples were taken two hours
after study drug initiation, every four hours until target
aPTT was reached and then every eight hours or as
deemed necessary by the treating physician. Routine blood
samples were taken at least every morning, according to
institutional routine. On-site screening for HIT was
performed using an enzyme-linked immunosorbent assay
for PF4/heparin (until December 2011: Haemochrom
Diagnostica GmbH, Essen, Germany since then Techno-
clone GmbH, Vienna, Austria) with a cut-off of 0.4 optical
density units. Sera of the study patients were further
tested by HIPA [14].
Control of study drug application: duration, infusion
rates and interruptions in application were documented.
Infusion rates of less than 0.1 ml/hour were assessed as
a stop of study drug infusion.
Statistics
Based on pilot data, a prolongation of mean hemodialysis
circuit life-time of 30 hours for lepirudin to 57 hours with
argatroban was considered to be clinically relevant (stand-
ard deviation 25 hours). A sample size of 15 renal replace-
ment patients per group (80% power, two-sided alpha 0.05)
required enrolment of 100 suspected HIT patients.
To allow comparison of coagulation variables at spe-
cific time points, values between two measurements were
linearly extrapolated.
Using IBM SPSS Statistics 21, we performed an inten-
tion to treat analysis and used t-test or U-test and
Chi-square or Fisher’s exact-test as appropriate with a
two-sided level of significance <0.05. For analysis over
time, Bonferroni corrections were applied. Kaplan-Meier
estimator with log rank test was used to analyze mean
filter life-time between the two groups.
Results
Study drugs were administered to 66 patients (Trial profile,
Figure 1), of whom 28 (42%) underwent continuous renal
replacement therapy. Initial patient characteristics did not
differ between the groups (Table 1). The study was termi-
nated by 31 March 2012, when delivery of lepirudin was
stopped by the manufacturer [15].
Primary endpoint
Mean life-time of a maximum of two consecutive dialysis
circuits did not differ significantly between the two groups
(Table 2 and Figure 2). Censoring filters which were ended
electively due to patient transfer, operation or diagnostic
testing did not alter our findings (data not shown). Mean
dialysis dose was 36 ± 18 ml/kg/hour and did not differsignificantly between groups, with a mean ultrafiltration
rate of 110 ml/hour.
Secondary endpoints
Secondary endpoints are summarized in Table 3. Signifi-
cant differences were found for the incidence of bleeding
complications and the time till target aPTT.
In the lepirudin group, bleeding complications occurred
in eleven patients which was a significantly higher rate
compared to only four patients with argatroban (odds
ratio (OR) 3.9, 95% confidence interval (CI) 1.1 to 14.0,
P = 0.040). Of note, eight of these eleven patients in the
lepirudin group suffered from diffuse bleeding from
drains, wound site, catheters, skin and upper airway mu-
cosa. In three patients, distinct bleeding sites were identi-
fied, that is, intrathoracic, intraabdominal (hepatic artery
following pancreatic surgery) and lower gastro-intestinal
tract. In one patient the actual bleeding source was not
identified although hemoglobin dropped to 6.5 mg/dl
without any explanation and transfusion was necessary.
The onset of bleeding occurred on day two in seven
cases, on day four in two cases and on day five in two
cases.
In the argatroban group, we observed gastrointestinal
bleeding in three patients. A fourth patient suffered from
hepatic insufficiency following extended liver resection,
requiring massive transfusion and surgical revision. The
onset of bleeding in argatroban patients occurred on
days 2, 4, 6 and 7.
In the lepirudin group, two patients developed new
thromboembolic events: one had a cerebral and the second
myocardial infarction. In the argatroban group, three pa-
tients had new thromboembolic events: one had cerebral
infarction, another pulmonary embolism and the third
suffered from myocardial infarction and gastrointestinal
ischemia (OR 0.7, 95% CI 0.1 to 4.4, P = 0.639).
Comparison of patients with and without relevant bleedings
There was no significant difference in aPTT values over
time between patients with and without bleeding (see
Additional file 1). Patients with bleeding were more likely
to suffer from chronic renal insufficiency (67% versus 6%,
P <0 001), to require renal replacement therapy (73%
versus 41%, P <0.001) and had a higher mortality rate
than those without (60% versus 12%, P <0.001). A detailed
comparison is included in Additional file 2.
HIT
Of all study patients, 15 (23%) were HIT positive with at
least an intermediate 4 T score and a positive HIPA test,
10 (29%) in the argatroban and 5 (16%) in the lepirudin
group (P = 0.240). The need for renal replacement therapy
did not differ between HIT and non-HIT patients (60%
versus 38%, P = 0.150) and mean filter life-time was
Figure 1 Trial flow chart. Data are presented as mean ± SD, n = number of patients, sec = seconds. SD, standard deviation.
Treschan et al. Critical Care 2014, 18:588 Page 4 of 8
http://ccforum.com/content/18/6/588also not different (26 ± 19 hours versus 31 ± 24 hours,
P = 0.606). There were no statistically significant differ-
ences in study drug dosing between HIT and non-HIT
patients. In HIT positive patients, three newly diagnosed
thromboembolic events (3/10, 30%) were detected in the
argatroban group as compared to none out of five in the
lepirudin group (P = 0.505).
Control of study drug application
The duration of study drug administration was signifi-
cantly shorter in the argatroban group (Table 3). There
were no significant differences in aPTT or infusion rates
over time (data not shown). Mean doses of study drugs
applied during the trial were as follows: lepirudin: 1)
patients with continuous renal replacement therapy:
6 ± 4 μg/kg/hour (n = 17), 2) patients with moderate renalimpairment (creatinine ≥1.3 mg/dl, n = 7): 9 ± 5 μg/kg/
hour and 3) patients without renal impairment (creatin-
ine <1.3 mg/dl, n = 8): 43 ± 43 μg/kg/hour; argatroban: 1)
patients with severe liver dysfunction (bilirubin ≥4 mg/dl,
n = 3): 0.1 ± 0.1 μg/kg/minute and 2) other patients
(n = 31) 0.5 ± 0.3 μg/kg/minute. Argatroban doses ten-
ded to be lower in patients on dialysis (0.33 ± 0.25 versus
0.55 ± 0.38 μg/kg/minute, P = 0.090).
Discussion
This is the first published randomized controlled double-
blind study comparing two direct-thrombin inhibitors in
critically ill surgical patients requiring alternative anticoa-
gulation following suspicion of HIT. The essential finding
was that argatroban and lepirudin are both equally effect-
ive with regard to anticoagulation and filter patency, while






Age (years) 68 ± 12 64 ± 17
Male (number) 24 (71%) 19 (59%)
Body mass index (kg/m2) 29 ± 9 26 ± 5
Simplified Acute Physiology Score II 35 ± 14 36 ± 14
SOFA score 10 ± 6 10 ± 4
Thromboembolic events (number) 11 (32%) 12 (38%)
Hemoglobin (g/dl) 10.1 ± 1.2 9.7 ± 1.0
Thrombocytes (per nl) 144 ± 124 152 ± 160
INR 1.2 ± 0.2 1.2 ± 0.3
aPTT (seconds) 46.1 ± 8.6 43.9 ± 7.9
Thrombin time (seconds) 27.7. ±29.2 19.0 ± 5.3
Duration of previous heparin
therapy (days)
16 ± 4 14 ± 12
Probability of HIT according to
4 T Score (number)
0/22/12a 3/23/6a
(low /intermediate/high) (0/65/35%) (9/72/19%)
General and visceral surgery (number) 10 7
Vascular surgery (number) 4 2
Cardiac surgery (number) 19 18
Others (number) 1 5
Chronic renal insufficiency (number) 6 7
a4 T Scores were obtained for one patient in the argatroban and for two
patients in the lepirudin-group with missing information and might therefore
be underestimated. Data are presented as mean ± SD or full numbers and
percentage in parenthesis. There were no statistically significant differences
between the groups. aPTT, activated partical thromboplastin time; HIT,
heparin-inducd thrombocytopenia; SD, standard deviation; SOFA = Sequential
Organ Failure Assessment; INR, international normalized issue.
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lower rate of clinically relevant bleeding complications.
However, absolute filter life-times are comparably short,
thus additional regional citrate anticoagulation could op-
timize filter patency in this specific patient population.
We had planned to study 30 patients with renal replace-
ment. Despite the early termination of the trial, we were
still able to study 28 of the 30 patients. The difference in
filter life-time between argatroban and lepirudin of onlyTable 2 Results of the primary endpoint of the trial comparin
Argatroban (number = 34)
Continuous renal replacement therapy 12 (35%)
Patients with two consecutive filters 9 (26%)
Life-time of first filter (hours) 33 ± 33
Life-time of second filter (hours) 29 ± 12
Average filter life time (hours) 32 ± 25
Data are presented as mean ± SD or full numbers and percentage in parenthesis. A
deviation.five hours yielded only a small effect size of 0.2 and is of
minor clinical relevance. Therefore, completion of the trial
as initially planned would not have had a significant effect
on our results. Argatroban and lepirudin demonstrate
equally effective anticoagulation of critically ill surgical
patients with continuous renal replacement therapy. How-
ever, filter life times were comparably low and if repeated
clotting occurred, we added regional citrate anticoagula-
tion, but did not quantify the resulting life-times. Regional
citrate anticoagulation is suggested as first choice in the
Kidney Disease: Improving Global Outcomes (KDIGO)
guidelines for acute kidney injury [16]. Therefore, based
on our results, adding regional citrate anticoagulation
could further optimize the treatment of critically ill pa-
tients suspected for HIT and renal replacement therapy.
It is important to note that regional citrate anticoagulation
does not substitute for alternative systemic therapeutic
anticoagulation in HIT patients. Patients with suspec-
ted or proven HIT require systemic anticoagulation in
therapeutic doses due to the pro-thrombotic nature of
the disease [17]. Our data show that in patients with con-
tinuous renal replacement therapy systemic anticoagula-
tion might not be sufficient to facilitate long filter patency.
Thus, addition of regional citrate anticoagulation should
be considered.
Our data suggest more moderate bleeding compli-
cations in the lepirudin group, despite similar aPTT and
platelet counts in both groups. Although the ecarin
clotting time is considered to be more appropriate,
aPTT is much more widely used in clinical practice and
has become accepted to guide anticoagulation by direct
thrombin inhibitors and thus we used it to titrate both
study drugs [18].
The significantly shorter time until the target aPTT
between 55 and 65 seconds was reached in the lepirudin
group does not explain the higher bleeding incidence, be-
cause argatroban patients did not reach the target aPTT
later due to under dosing but rather because of an initial
‘overshoot’, defined as a first aPTT above 65 seconds.
Moreover, this overshoot in anticoagulation was not asso-
ciated with an increased incidence of bleeding.
Despite very cautious administration of anticoagulants,
more patients who underwent renal replacement therapyg the filter life-time between groups
Lepirudin (number = 32) P-value 95% Confidence interval
16 (50%) 0.227
12 (37%) 0.424
22 ± 22 0.298 −10 – 33
34 ± 34 0.681 −30 – 20
27 ± 21 0.574 −13 – 23
P-value of <0.05 was considered to be statistically significant. SD, standard
Table 3 Comparison of secondary endpoints and study








Bleeding (number) 4 (12%) 11 (34%) 0.040
Moderate (number) 2 (6%) 8 (25%) 0.041
Severe (number) 2 (6%) 3 (9%) 0.667
Packed red blood cells (Units) 3 ± 8 4 ± 5 0.488
Fresh frozen plasma (Units) 3 ± 12 2 ± 5 0.582




3 (9%) 2 (6%) 0.639
Anaphylactoid reactions
(number)
1(3%) 2 (6%) 0.608a
Length of ICU stay (days) 24 ± 22 32 ± 32 0.213
Length of hospital stay (days) 54 ± 41 53 ± 55 0.919
In-hospital mortality (number) 6 (18%) 9 (28%) 0.389
Time until target aPTT of 55
to 65 seconds (hours)
20 ± 19 11 ± 9 0.017
Time until aPTT ≥55
seconds (hours)
12 ± 16 8 ± 6 0.189
Patients with first
aPTT >65 seconds (number)
9 (26%) 4 (12%) 0.213
First aPTT >65
seconds (seconds)
69 ± 3 74 ± 10 0.389
Study drug application
Duration of study drug
application (hours)
103 ± 47 126 ± 37 0.030
Infusion rate (ml/hour) 4.1 ± 2.9 3.8 ± 2.5 0.654
Interruption in study drug
application (number)
12 (35%) 14 (43%) 0.615
Cumulative duration
of interruptions (hours)
33 ± 39 34 ± 39 0.860
aNone of the anaphylactoid reactions was attributed to the study drugs. Data are
presented as mean ± SD or full numbers and percentage in parenthesis. A P-value
of <0.05 was statistically significant. Further details on secondary endpoints are
explained in the text.
Figure 2 Kaplan-Meier analyses of time till filter clotting.
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Patients with renal failure have an increased risk of
bleeding due to impaired platelet function, vessel wall
abnormalities and changes in the coagulation cascade
[19]. However, a detailed analysis of factors contributing
to these findings is beyond the scope of this trial.
Our trial design was unusual, as not all patients with
suspected HIT could be expected to reach the primary
endpoint. We recruited patients at the time point when
HIT was suspected, need for renal replacement therapy
was not an inclusion criterion. Restricting inclusion to
patients who were undergoing hemodialysis at the time
point of HIT suspect would have made the trial nearly
impossible to conduct in a single center. After intensive
discussion with our IRB and our national regulatory
board, it was advised to include all patients suspected of
having HIT into the trial, because alternative anticoagu-
lation is required in these cases. We restricted the meas-
urement to a maximum of two filters, because repeated
clotting is expensive and poses an unnecessary risk to
patients due to transfusion of packed red cells. Thus,
according to clinical routine, we added regional citrate
anticoagulation after clotting of the second filter.
As lepirudin is not marketed anymore, our observa-
tions have two major clinical implications with regard to
argatroban.
First, a target aPTT of 1.5 to 2 times baseline, which
we had chosen for both drugs based on our previous
experience [20,21], is adequate in critically ill surgical
patients with suspected HIT. The argatroban group in
our study experienced a bleeding incidence of 12%
(4/34) and thromboembolic complications in 8.8% (3/34).Doepker et al. found significantly higher incidences of
bleedings, but similar thromboembolic complications in a
mixed population of medical and surgical patients with
argatroban anticoagulation adjusted to a baseline of 2
to 2.5 [22].
Second, patients with thrombocytopenia, persisting for
at least 24 hours postoperatively, a 4 T score >3 indicating
at least an intermediate risk for HIT or a positive PF4/
heparin immunoglobulin G (IgG) ELISA, should receive
alternative anticoagulation, despite other potential causes
for thrombocytopenia. Using these criteria, we found as
many as 23% of our patients to suffer from HIT, defined
as a positive HIPA test.
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cion of HIT and for the decision about alternative anticoa-
gulation [23]. Consistent with a recent meta-analysis, the
positive predictive value of the 4 T score for HIT was
moderate and the majority of patients with confirmed
HIT had only an intermediate risk score [12]. Additionally,
the positive predictive value of positive PF4/heparin IgG
ELISA was also low. These tests often detect antibodies,
which may not necessarily be the cause of the clinical
symptoms of HIT [24,25]. Therefore, even with careful
application of the 4 T score and HIT ELISA testing, a sub-
sequent platelet activation assay is indispensable to prove
or rule out HIT in critically ill patients.
Limitations of the trial
This is a single-center trial, conducted pragmatically
close to clinical routine in a limited number of critically
ill surgical patients. Therefore, our data may not be used
to generalize the effects on other patient populations.
The early termination of the trial is, however, a major
limitation. Nevertheless, data on the safe and appro-
priate application of argatroban are important for the
treatment of surgical patients because this population is
at highest risk for bleeding. With regard to the com-
parable aPTTs in both groups, we consider the dosing
regimens clinically appropriate for critically ill surgical
patients.
The comparably low filter life-times measured in this
trial might not only relate to the systemic anticoagulation,
but are also influenced by other factors, such as filter area,
blood flow and filtration fraction. Thus, we are not
promoting our renal replacement strategy but provide a
comparison of argatroban and lepirudin under the same
premises. Further research is needed to address ways to
improve filter patency in patients with HIT requiring
continuous renal replacement therapy.
Conclusions
Argatroban and lepirudin provide equally effective antic-
oagulation in critically ill surgical patients requiring con-
tinuous renal replacement therapy. In patients receiving
lepirudin compared to argatroban, we observed a signifi-
cantly higher incidence of clinically relevant bleeding
complications. Accordingly, the results of our trial support
the use of argatroban in patients with clinically suspected
or confirmed HIT, who require continuous intravenous
anticoagulation.
Key messages
 In critically patients, suspected of heparin-induced
thrombocytopenia undergoing continuous renal
replacement therapy, filter-life time is comparable
between argatroban and lepirudin. Argatroban is associated with a lower risk of
bleeding in critically ill patients.
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Additional file 1: Comparison of aPTT over time between patients
with and without relevant bleedings. Data are presented as mean ± SD.
There was no significant difference.
Additional file 2: Comparison of patients with and without bleeding.
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